Bleomycin Sulfate and Trastuzumab-dkst Intravenous

• Generic Name: bleomycin
• Dosage Forms: n.a.
• Other Brand Names: Bleo 15k, Blenoxane

Treatment of Hodgkin’s disease.

Combination therapy for induction of remissions is superior to single-drug therapy.

Various combination regimens are used.

Commonly used in combination with doxorubicin, vinblastine, and dacarbazine (ABVD regimen).

Has been used for treatment of non-Hodgkin’s lymphoma.

Second- or third-generation combination regimens containing bleomycin no more effective than the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) for the treatment of advanced intermediate-grade or high-grade non-Hodgkin’s lymphoma.

Treatment of testicular embryonal cell carcinoma, choriocarcinoma, and teratocarcinoma.

Combination chemotherapy with bleomycin, cisplatin, and etoposide is a regimen of choice for the treatment of advanced nonseminomatous testicular carcinoma.

Combination chemotherapy with bleomycin, cisplatin, and etoposide is used for the treatment of disseminated seminoma testis.

Intracavitary injection as a sclerosing agent for intrapleural management and prevention of recurrent pleural effusions (pleurodesis) caused by metastatic tumors.

At least as effective and possibly better tolerated than intrapleural tetracycline.

Intrapleural talc may be preferred because of cost considerations.

Has been used for intrapleural management of pneumothorax associated with AIDS Pneumocystis jiroveci (Pneumocystis carinii) pneumonia.

Palliative treatment of squamous cell carcinomas of the head and neck (including mouth, tongue, tonsils, nasopharynx, oropharynx, sinuses, palate, lip, buccal mucosa, gingiva, epiglottis, larynx, skin).

Poorer response to bleomycin in patients who have received prior radiation therapy for the treatment of head and neck cancer.

Combination chemotherapy with cisplatin, methotrexate, and vincristine for advanced head and neck cancer.

Has been used for palliative treatment of squamous cell carcinoma of the cervix.

Not considered a drug of choice for the treatment of advanced cervical cancer.

Palliative treatment of squamous cell carcinomas of the penis and vulva (in combination with other antineoplastic agents).

Has been used for the palliative treatment of AIDS-related Kaposi’s sarcoma (alone or in combination with doxorubicin, and a vinca alkaloid).

Has been used as monotherapy for palliative treatment of early-stage disease.

Bleomycin combination chemotherapy has been considered a regimen of choice for advanced disease, but a liposomal anthracycline currently considered first-line therapy.

Has been used for the treatment of ovarian germ cell tumors (in combination with cisplatin and etoposide).

Has been used for the treatment of intracranial germ cell tumors (in combination with cisplatin and vinblastine).

• Generic Name: trastuzumab
• Dosage Forms: n.a.
• Other Brand Names: Herceptin, Kanjinti, Ogivri

Trastuzumab-dkst injection is used alone or together with other cancer medicines (eg, carboplatin, cyclophosphamide, docetaxel, doxorubicin, paclitaxel) to treat HER2-overexpressing new or metastatic (cancer that has spread) breast cancer.

Trastuzumab-dkst injection is also used in combination with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic (cancer that has spread) stomach and gastroesophageal (stomach and esophagus) cancer.

Trastuzumab-dkst prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).

Trastuzumab-dkst is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-dkst, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, such as a skin rash, may not be serious but may cause concern. Some effects do not occur until months or years after the medicine is used.

Trastuzumab-dkst is to be given only by or under the immediate supervision of your doctor.